Board of Directors

Colin Hill

Chairman, CEO and Co-Founder

Jan Berger, MD, MJ

President & Chief Executive Officer, Health Intelligence Partners; Vice Chair

Craig Cimini

Vice President of Strategy and Business Development & Cigna Ventures, Cigna

Rob Coppedge

President &Chief Executive Officer, Echo Health Ventures

Adrian Weller, PhD

Senior Research Fellow, University of Cambridge Programme Director, Artificial Intelligence, The Alan Turing Institute

Board Observers

Roberto Barzi

President &Co-Founder and Managing Director, Fort Rock Capital

David W. Miller, Ph.D.

Operating Partner, GHO Capital

Scott Musch

Vice President, Corporate Development, Cambia Health

Janis Naeve

President & Managing Director, Amgen Ventures

Vijay Venkatesan

Vice President and Chief Analytics Officer, Horizon BCBSNJ

Shin Serizawa

Director, IT & Communication Business Dept., Mitsui & Co, (U.S.A.) Inc.

Joel Krikston

Managing Director Venture Investments/Head of Strategic Innovation Alliances, Merck Global Health Innovation Fund

Jeff Staiger

Vice President, Immunology, Fibrosis and Digital Health Business, Bristol-Myers Squibb

Our Investors

{"infinite":"true","pause_on_hover":"false","adaptive_height":"false","items":"5","auto_play":"true","speed":"1000","rtl_mode":"false","dots":"false","nav":"false","slides_to_scroll":"1","slides_to_scroll_mobile":"1","auto_play_speed":"1000","draggable":"true","swipe":"true","lazy":"false","carousel_mode":"standard","center_mode":"false","center_mode_padding":"60px","vertical":"false","nav_type":"nav_arrow","items_desktop":"4","items_desktop_small":"3","items_tablet":"2","items_mobile":"1","nav_arrow_type_horizon":"angle_arrow_horizon"}

Jan Berger, MD, MJ

President & Chief Executive Officer,Health Intelligence Partners

Vice Chair of GNS Board of Directors

Jan founded Health Intelligence Partners six years ago as a health care consultancy that blends more than thirty years of business and clinical experience. Health Intelligence Partners has a global focus, working with clients on both short -term and long-term healthcare business strategies and solutions. Jan and Health Intelligence Partners help clients navigate the healthcare environment in order to identify and articulate value opportunities. A great deal of Jan’s focus is on consumer engagement and how it affects the decisions that the consumer makes and the actions that they take.

Prior to founding Health Intelligence Partners, Jan served as Senior Vice President and Chief Clinical Officer for CVS Caremark. During that time, she had Executive Management, P & L, Operations, Innovation and Strategy responsibilities. Before going to CVS Caremark, Jan had 15 years’ experience in healthcare administration within the health plan and academic arenas and lead operations for two population health companies.

As a veteran healthcare executive, Jan’s leadership has delivered results in a variety of settings. Jan offers her experiences and insights through her consulting agency as well as through her participation on healthcare and consumer product boards. She presently sits on healthcare focused boards including AccentCare (Chair; Compliance Committee, Compensation Committee), GNS Healthcare, The University of Arizona School of Pharmacy, Harvard Patient Safety Board, Midwest Business Group on Health and Population Health Alliance (Chair: Government Affairs Committee). Jan’s consumer focused boards include Meals to Heal and Whiskerdocs. Jan previously sat on two boards; Care Core National (Committees: Chari: Finance Past Chairperson, Compensation, Search, M&A and Strategic Directions) and Rx-Ante, which were recently sold. She also sits on numerous business and healthcare committees.

As the author of the books “Leveraging Health” and “Thirteen Common Pitfalls in Consumer Engagement” and “Medical Liability for Pediatricians”, the Editor in Chief of American Journal of Pharmacy Benefit and on the editorial boards of a number of healthcare journals, Jan is considered a national health care thought leader. Jan speaks and writes on a broad range of health care issues.

Jan holds both a Doctor of Medicine degree and a Master’s degree in Jurisprudence from Loyola University in Chicago and a Certificate in Healthcare Business Administration from University of South Florida. She also holds a black belt in Six Sigma. Jan is an assistant professor at Northwestern University School of Medicine in Chicago, Illinois.

Craig Cimini

Vice President of Strategy and Business Development & Cigna Ventures, Cigna

Board Member

Biography coming soon.

Rob Coppedge

Chief Executive Officer, Echo Health Ventures

Board Member

As CEO of Echo Health Ventures, Rob leads the company’s efforts to identify, invest in and grow innovative companies that enable and deliver a transformed experience to health care consumers nationwide. As part of Echo’s unique partnership with its parents, Rob works closely with the senior management teams and board of Cambia Health Solutions and Mosaic Health Solutions to support collaboration with Echo’s portfolio companies, accelerate Cambia and Mosaic’s strategies and more quickly bring health care innovation to national scale.

Rob has more than 20 years of experience in health care venture capital and business building. Before founding Echo, Rob served as the President of Cambia Health Solutions’ diversified business unit (Direct Health Solutions). In this role, Rob oversaw Cambia’s wholly-owned operating companies (including cost and quality transparency market leader HealthSparq; ancillary benefits provider LifeMap) as well as its venture and private equity investing activities. Rob joined Cambia in 2010 to launch and build the company’s diversification and corporate venture investment efforts. Under Rob’s leadership, Cambia invested in nearly 20 companies.

In 2015, Rob cofounded the Cambia Grove – an innovation hub focused on catalyzing and supporting the Pacific Northwest’s emerging health care economic cluster. At the Cambia Grove, innovators and entrepreneurs work closely with regional stakeholders to find solutions to pressing health care challenges.

Before joining Cambia, Rob was the founding partner of Faultline Ventures, where he worked with numerous early stage companies and strategic investors. Previously, he was a Partner at Capitol Health Partners, a Washington, D.C., and New York City-based venture capital firm specializing in early-stage health services and health care information technology.

Active in industry and community organizations, Rob serves on the boards of several health care companies and is a founder and former director of the Nashville-based largest network of young health care executives, Leadership Health Care. Rob also serves on the board of directors at Life Science Washington (formerly Washington Biotechnology & Biomedical Association) and the Oregon Museum of Science and Industry (OMSI) and is a member of the American Leadership Forum.

Rob is a graduate of Georgetown University with a degree in history and is a Chartered Financial Analyst, charter holder.

Adrian Weller, PhD

Senior Research Fellow, University of Cambridge Programme Director, Artificial Intelligence, The Alan Turing Institute

Board Member

Adrian is a Senior Research Fellow in the Machine Learning Group at the University of Cambridge, in the Computational and Biological Learning Lab, and also serves as a Faculty Fellow at The Alan Turing Institute, the United Kingdom’s national institute for data science. Most of his academic research relates to graphical models, but he is also very interested in other areas including finance, anything on intelligence (natural or artificial), deep learning, reinforcement learning, evolution, Bayesian methods, time series analysis, ethics, music and methods for big data.

Prior to his current roles, Adrian served as a Managing Director at Citadel Investment Group where he ran US and European interest rate trading. Earlier, Adrian was in the fixed income proprietary trading group at Salomon Brothers, and previously ran the fixed income options desk at Goldman Sachs.

Adrian completed his PhD in Computer Science from Columbia University, and holds a BA and MA in Mathematics from Trinity College, Cambridge. He is an active angel investor, board member and advisor to many companies and charities apart from GNS including Simplex, Cambridge in America, and the Coexist Foundation.

Roberto Barzi

Co-Founder and Managing Director, Fort Rock Capital

Board Observer

Roberto is a founder and managing director of Fort Rock Capital, a London-based investment firm focused on direct healthcare investments. He has more than fifteen years’ experience in private equity and venture capital, including with the international investor 3i, where he was a leading member of the global healthcare group based in London.

He is a director of numerous lifescience businesses across Europe, including Vasopharm (therapeutics, Germany) and Medinet Clinical Services (UK).

Roberto previously worked in mergers and aquisitions in New York and London. He holds an MBA with honors from the Wharton School and a business degree from Universita’ Bocconi, Italy.

David W. Miller, Ph.D.

Operating Partner, GHO Capital

Board Observer

Dave is an accomplished global pharmaceutical executive and advisor with over 25 years of experience. He is an Operating Partner at GHO Capital, focusing on health care investments. He also operates a specialty advisory practice, advising pharmaceutical executives on pricing, access and health economic and outcomes research strategies. From 2010 to 2017, he was Senior Vice President of Global Market Access at Biogen. He previously worked at Elan, holding roles as Vice President of Pharmacoeconomics and Managing Director. Dr. Miller began his pharmaceutical industry career at GlaxoSmithKline in pharmacoeconomics and assumed increasing responsibilities towards becoming Vice President of Global Health Outcomes. A dual US/UK citizen, he has lived and worked in Europe, Asia and the US. Dr. Miller is the author or co-author of over 70 scientific publications. He is a member of advisory boards at the University of Maryland Baltimore, the University of Washington and Tufts University, and a board member of the Walther Foundation, a charitable organization supporting youth education in the San Francisco Bay Area. He previously served on the Board of Directors of Elan Pharma Ltd and the National Pharmaceutical Council, and was Chair of the Board of Grants for the American Foundation for Pharmaceutical Education. He holds a degree in pharmacy from the University of Iowa and earned his PhD in pharmacy administration at the University of Maryland Baltimore, where he studied health economics and policy.

Scott Musch

Vice President, Corporate Development, Cambia Health

Board Observer

Scott serves as Vice President of Corporate Development at Cambia Health Solutions.

He helps to lead all health plan related M&A, divestitures, and strategic partnerships for Cambia Health Solutions. Prior to joining Cambia in April 2011, Scott worked in investment banking for over twelve years, covering a wide variety of companies, both inside and outside the healthcare industry. He was formerly a Senior Vice President for healthcare services-focused investment bank Shattuck Hammond Partners and prior to that, he worked as a Vice President in the North American Mergers and Acquisitions Department at J.P. Morgan Securities, Inc.

Scott earned an MBA from the Tuck School of Business at Dartmouth College, where he was a Tuck Scholar. He graduated with honors from the University of Pennsylvania, where he received a BS in Finance from the Wharton School and a BA in Economics from the College of Arts and Sciences. He is currently studying for his Doctorate of Health Administration at Central Michigan University.

Janis Naeve

Managing Director, Amgen Ventures

Board Observer

Janis Naeve, Managing Director of Amgen Ventures, joined Amgen in 2005 and directs the company’s corporate venture capital fund focused on early-stage biotechnology companies discovering and developing human therapeutics as well as digital health and healthcare IT. Janis came to Amgen from X-Ceptor Therapeutics where she was Director of Corporate Development and supported the acquisition by Exelixis. Prior to this she was Director of Business Development at Aurora Biosciences where she led transactions for the ion channel technology business unit and managed the collaborations with Pfizer, Merck, Lilly, and Bristol Myers-Squibb. Janis holds a PhD in pathology from University of Southern California and completed a post-doctoral fellowship at the California Institute of Technology.

Vijay Venkatesan

Vice President and Chief Analytics Officer, Horizon BCBSNJ

Board Observer

Vijay Venkatesan is Vice President and Chief Analytics Officer at Horizon BCBSNJ, the state’s largest health insurer, with over 3.8 million members. In his role, Mr. Venkatesan is responsible for overseeing the next-generation data and analytics strategy to support business operations and diversification strategies as the Company advances its OMNIASM Health Alliance partnerships and health care transformation.

Prior to joining Horizon BCBSNJ, Mr. Venkatesan served as the Chief Data Officer at Providence St. Joseph Health, where he was responsible for driving a progressive data and analytics strategy that included the organization’s transition to the Cloud and Artificial Intelligence. He created a data marketplace for self-service data and mobile platforms for enabling intelligence-based actions to support the organizational strategy.

Mr. Venkatesan also served as Vice President of Enterprise Data Management for Sutter Health. Under his leadership, Sutter Health made great strides advancing its capabilities around data, reporting and analytics. He was instrumental in advancing several regional and system-wide strategic priorities to support the shared savings program, advanced illness management, electronic medical record (EMR) reporting and other quality-related initiatives. Mr. Venkatesan also served as Vice President of analytics and business intelligence for Sutter’s Physician Services.

Before joining Sutter, he was Vice President of Management Information and Analysis with Kaiser Permanente for four years where he helped lead Kaiser Permanente’s data and analytics transformation.

Mr. Venkatesan holds a Bachelor of Science degree in Computer and Information Science from Cleveland State University and a Master’s of Business Administration degree from the Ross School of Business, University of Michigan.

Shin Serizawa

Director, IT & Communication Business Dept., Mitsui & Co, (U.S.A.) Inc.

Board Observer

Shin Serizawa joined the company in 2003, and has engaged in various projects including its business process reengineering, ERP installation at their overseas office, and building the alliance between the AOL Platforms Japan (which has become Oath Japan) and local internet advertisement agencies in China. He has also taken initiative to form a strategic partnership with Drawbridge in July 2017 and has been working to expand its business in Japanese market since then.

Joel Krikston

Managing Director Venture Investments / Head of Strategic Innovation Alliances, Merck Global Health Innovation Fund

Board Observer

Joel Krikston is Managing Director Venture Investments and Head of Strategic Innovation Alliances. Joel is focused on identifying new investment opportunities with a focus on Oncology, Vaccines and Infectious Disease. Mr. Krikston has over 20 years of experience in healthcare innovation. Prior to joining Merck GHI, he was an Investment Principal at Johnson & Johnson Development Corporation. Joel also spent over eight years as an investment banker, covering an array of healthcare clients and included experience at BNP Paribas, JPMorgan and ABN Amro. Joel has an MBA from the Stern School of Business at NYU and completed his Bachelor’s degree in Finance and International Business at Fairfield University.

Jeff Staiger

Vice President, Immunology, Fibrosis and Digital Health Business, Bristol-Myers Squibb

Jeff Staiger is Vice President, Immunology, Fibrosis and Digital Health Business, based in Summit, NJ is responsible for setting and executing the BMS externalization strategy for the therapeutic areas of Immunology and Fibrosis and for Digital Health initiatives.

Jeff is an accomplished business development leader with broad transactional experience including closing Collaboration & License Agreements, Acquisitions, Equity Investments, Terminations and Renegotiations. Highlights include transactions with Skyhawk Therapeutics, IBM Watson, Acceleron, FORMA, VentiRx, Acetylon and the Recombinant Antibody Network.

During his 12 years at Celgene, Jeff has gained broad experience in Finance, Clinical Development, Corporate Strategy, Commercial Operations, Alliance Leadership and Business Development.

Prior to joining Celgene and following obtaining degrees in Economics and Accounting at Gordon College, Jeff started his career at PricewaterhouseCoopers becoming a Certified Public Accountant.